Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is expected to report third quarter earnings results, after market close, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 1.87 per share.
Looking ahead, the full year loss are expected at $ 7.61 per share on the revenues of $ 2.73 million.
Stock Performance
On Friday, shares of Arena Pharmaceuticals, Inc. has traded high as $ 88.00 and has cracked $ 85.64 on the downward trend, reaching $ 86.64 with volume of 437.80 thousand shares.
According to the previous trading day, closing price of $ 86.64, representing a 161.58 % increase from the 52 week low of $ 32.95 and a 4.44 % decrease over the 52 week high of $ 90.19.
The company has a market capital of $ 4.99 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 30th September 2020, maintained by Bank of America at Buy rating, with $ 85.00 target price.
Conference Call
Arena Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.arenapharm.com
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohns disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure.
